MNG135
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.464
- INTERFERON_GAMMA_RESPONSE+0.396
- UNFOLDED_PROTEIN_RESPONSE+0.360
- MYC_TARGETS_V2+0.340
- IL6_JAK_STAT3_SIGNALING+0.329
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.301
- ALLOGRAFT_REJECTION+0.282
- NOTCH_SIGNALING+0.272
- WNT_BETA_CATENIN_SIGNALING+0.271
- TGF_BETA_SIGNALING+0.263
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.298
- SPERMATOGENESIS-0.274
- KRAS_SIGNALING_DN-0.152
- BILE_ACID_METABOLISM-0.069
- FATTY_ACID_METABOLISM-0.058
- XENOBIOTIC_METABOLISM-0.024
- ESTROGEN_RESPONSE_LATE-0.020
- ESTROGEN_RESPONSE_EARLY-0.006
- ANDROGEN_RESPONSE+0.000
- IL2_STAT5_SIGNALING+0.029
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.891 |
| 2 | A9B59C46-7F32-4DD1-9649-B1788CA5E909 | — | — | 0.891 |
| 3 | SRR934949 | — | — | 0.884 |
| 4 | SRR934946 | — | — | 0.880 |
| 5 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.876 |
| 6 | TCGA-FD-A5BU-01A-31R-A26T-07 | — | — | 0.874 |
| 7 | 1B1E827B-A98A-465E-AC6F-448C076E829D | — | — | 0.872 |
| 8 | C33EDB64-C7B9-49A1-AE73-1D293F8522F6 | — | — | 0.871 |
| 9 | SRR934722 | — | — | 0.870 |
| 10 | TCGA-UY-A9PB-01A-11R-A38B-07 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.464 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.396 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.329 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.301 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.282 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.272 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.271 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.263 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.248 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.236 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.234 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.214 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.187 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.187 | Idelalisib | — uncovered |
| APOPTOSIS | 0.177 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.165 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.164 | Inavolisib | — uncovered |